Patterns and persistence of SARS-CoV-2 seropositivity among college students at Indiana University-Bloomington.

Patterns and persistence of SARS-CoV-2 seropositivity among college students at Indiana University-Bloomington.

Publication date: Sep 22, 2025

This study examined the patterns and persistence of SARS-CoV-2 seropositivity among college students from March to November 2020. Using data from a sample of students at Indiana University, we assessed (1) the duration and seropositivity following reverse transcription-PCR (RT-PCR)-confirmed SARS-CoV-2 infection and (2) persistence of seropositivity over 10 weeks between two laboratory antibody test visits. The longitudinal study was conducted at Indiana University from September to November 2020, with two laboratory antibody tests, and included self-reported RT-PCR results before the observational period from as early as 20 March 2020. This 6-9 month period contributes to our understanding of seropositivity dynamics. The study included 172 college students who had previously tested positive for SARS-CoV-2 and measured their seropositivity. Our results showed a notable decline (66. 7%) in antibody positivity over the observed period. Additionally, 12 weeks postinfection, most students with a SARS-CoV-2 infection history (75%) were no longer seropositive. These findings reveal a nuanced picture of antibody dynamics, highlighting the complex interplay of factors among college students. The study underscores the need for continued research on antibody levels among young adults to better understand the drivers of variations in antibody persistence. #NCT04620798.

Open Access PDF

Concepts Keywords
Indiana Adolescent
Nct04620798 Adult
Pcr antibodies
September Antibodies, Viral
Students Antibodies, Viral
college students
COVID-19
COVID-19 Serological Testing
dynamics
Female
Humans
Indiana
Longitudinal Studies
Male
public health
SARS-CoV-2
SARS-CoV-2
Seroepidemiologic Studies
Students
Universities
Young Adult

Semantics

Type Source Name
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO history
drug DRUGBANK Tropicamide
disease MESH viral infections
pathway REACTOME Immune System
disease MESH infections
drug DRUGBANK Guanosine
disease IDO infection
disease IDO symptom
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Etoperidone
disease IDO blood
disease IDO assay
drug DRUGBANK Gold
disease IDO quality
disease IDO immune response
disease MESH Reinfections

Original Article

(Visited 7 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *